Nightly sublingual tizanidine HCl in multiple sclerosis: Clinical efficacy and safety

Clinical Neuropharmacology

Volumn 33, Issue 3, 2010, Pages 151-154

  Vakhapova, Veronika ^a   Auriel, Eitan ^a   Karni, Arnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adrenergic agonist; Multiple sclerosis; Somnolence; Spasticity; Sublingual tizanidine HCl

Indexed keywords

PLACEBO; TIZANIDINE;

ADULT; AGED; ARTICLE; ASHWORTH SCALE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GLOBAL ASSESSMENTS OF DISEASE SEVERITY AND CHANGE; HUMAN; MALE; MULTIPLE SCLEROSIS; POOR GENERAL CONDITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SPASTICITY; TREATMENT OUTCOME; XEROSTOMIA;

ADMINISTRATION, SUBLINGUAL; ADRENERGIC ALPHA-AGONISTS; ADULT; CLONIDINE; CROSS-OVER STUDIES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PATIENT DROPOUTS; RECEPTORS, ADRENERGIC, ALPHA-2; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 77953173054     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181daad7d     Document Type: Article

References (16)

1. Currie R. Spasticity: a common symptom of multiple sclerosis. Nurs Stand 2001;15:47-55.
2. Goldstein M. Spasticity management: an overview. Neurology 2001;16:16-23.
3. Brar SP, Smith MB, Nelson LM, et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil 1991;72:186-189.
4. Iriarte J, Subira ML, Castro P. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler 2000;6:124-130.
5. Clark CM, Fleming JA, Li D, et al. Sleep disturbance, depression and lesion site in patients with multiple sclerosis. Arch Neurol 1992;49:641-643.
6. Bamer AM, Johnson KL, Amtmann D, et al. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 2008;14:1127-1130.
7. Merlino G, Fratticci L, Lenchig C, et al. Prevalence of 'poor sleep' among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med 2009;10:26-34.
8. Ferini-Strambi L, Filippi M, Martinelli V, et al. Nocturnal sleep study in multiple sclerosis; correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci 1994;125:194-197.
9. Tachibana N, Howard RS, Hirsch NP, et al. Sleep problems in multiple sclerosis. Eur Neurol 1994;34:320-323.
10. Bensmail D, Quera Salva MA, Bensmail D, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 2006;67:1432-1436.
11. Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-452.
12. Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997;54:731-736.
13. Saper JR, Lake AE 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002;42:470-482.
14. Zanaflex (Elan). Physicians' Desk Reference. 58th ed. Montvale, NJ: Thomson; 2004:1229.
15. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
16. Platz T, Eickhof C, Nuyens G, et al. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 2005;27 (1-2) : 7-18.